ArticleArtificial organs2026
Impact of Gentamicin-Impregnated Collagen Sponge on the Incidence of Access Related Infections After Full-Support Microaxial Flow Pump Therapy.
Article in Artificial organs, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSurgically implanted microaxial flow pumps (mAFP) are increasingly used for cardiogenic shock treatment. Standard mAFP explantation is performed bedside with a shortening of the vascular prosthesis, which may represent a potential source of infection in future. We analyzed the impact of gentamicin-impregnated collagen sponge (GICS) application in the wound during mAFP explantation on the incidence of prosthetic graft infections.
methodsBetween 01/2020 and 07/2024, 235 patients underwent bedside full-support mAFP explantation at our institution. Since 11/2022, GICS has been routinely applied in 115 patients, while 120 previously were treated without it.
resultsIn the GICS-group, after a median follow-up of 221 [24; 351] days, 17 (14.8%) patients developed graft infection, resulting in 0.23 events per patient year (EPPY); surgery was necessary in 16 patients (13.9%). In the control group, after a median follow-up of 399 [113; 654] days, infection occurred in 14 (11.7%) cases, 0.10 EPPY; surgical removal of the graft was necessary in 12 (10%). The GICS-groups presented an increased risk for graft infections: sHR 2.49 [1.11; 5.59], p = 0.027. After propensity score matching for relevant demographic parameters, there was no significant difference in the risk reduction of total graft infections sHR 1.92 [0.79; 4,72], p = 0.15.
conclusionsLocal application of GICS did not reduce the risk of access site infections in patients undergoing bedside explantation of mAFP from the graft surgically anastomosed to an axillary artery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.